Indivior Shares Fall 23% On Warning Of 2025 Revenue Decline

Shares in drugmaker Indivior (LSE:INDV) fell sharply in early trading after the company sounded the alarm over its 2025 revenues, despite a solid performance in 2024.

The company, which makes treatments for opioid addiction, expects revenue to drop 17% in 2025 as sales of Suboxone Film fall because of intense generic competition, and the company’s schizophrenia drug Perseris being discontinued.

Invidior’s 2024 total revenue rose 9% to $1.19 billion, driven by a 20% increase in sales of its flagship long-acting treatment for opioid use disorder, Sublocade. However, growth is expected to stall in 2025 because of competition in the US and funding challenges in the justice system.

The company plans to cut over $100 million in costs, and reinvest around $50 million in expanding its opioid treatment pipeline.

 

CLICK HERE TO REGISTER FOR FREE ON ADVFN, the world's leading stocks and shares information website, provides the private investor with all the latest high-tech trading tools and includes live price data streaming, stock quotes and the option to access 'Level 2' data on all of the world's key exchanges (LSE, NYSE, NASDAQ, Euronext etc).

This area of the ADVFN.com site is for independent financial commentary. These blogs are provided by independent authors via a common carrier platform and do not represent the opinions of ADVFN Ltd. ADVFN Ltd does not monitor, approve, endorse or exert editorial control over these articles and does not therefore accept responsibility for or make any warranties in connection with or recommend that you or any third party rely on such information. The information available at ADVFN.com is for your general information and use and is not intended to address your particular requirements. In particular, the information does not constitute any form of advice or recommendation by ADVFN.COM and is not intended to be relied upon by users in making (or refraining from making) any investment decisions. Authors may or may not have positions in stocks that they are discussing but it should be considered very likely that their opinions are aligned with their trading and that they hold positions in companies, forex, commodities and other instruments they discuss.

Comments are closed

WHAT IS ADVFN?

ADVFN covers all things stock market.

From the news and opinion pieces on pages like this to share discussion forums, charting tools, financials, live share prices and Level 2, order book data

If you trade or invest ADVFN has the tools you need to make the right decisions.

• 

  101 Ways to Pick Stock Market Winners

  You need the number one bestselling investment guide, the definitive text for day traders, investors and stock pickers.

• 

  The Death of Wealth

  Dissecting the global economy and the financial markets, the book lays out the evidence for the next economic game changer: the Death of Wealth.

• 

  Francois Normandeau

• 

  Quoted Data

• 

  Kenneth G. Mondero

• 

  James Cummings